# Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

> **NCT00568815** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 31 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Rituximab combined with ESHAP

## Key facts

- **NCT ID:** NCT00568815
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2012-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568815, "Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00568815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*